Improving Clinical Trials In Psychiatric Health Care

An Interview With 2022 Rising Leader Kiri Granger

Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.

shapes
• Source: Alamy

Rising Leaders Home

Central nervous system disorders represent a huge and growing unmet health need, yet drug development has stalled for some conditions...

More from Leadership

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.